Top-News
Biotechnologie Frankreich

Nanobiotix SA News

Aktie
WKN:  A1J7EB ISIN:  FR0011341205 US-Symbol:  NNBXF
5,67 €
-0,385 €
-6,36%
02.05.24 15:00:33
Handeln Depot/Watchlist
Aktienanzahl *
47,11 Mio.
Marktkapitalisierung *
277,71 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 26.03.2024

Nanobiotix SA News

04.12.23 - GlobeNewswire
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent ...
07.11.23 - GlobeNewswire
NANOBIOTIX Announces Closing of Global Offering
PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-​clinical stage ...
06.11.23 - GlobeNewswire
NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M
PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-​clinical stage ...
02.11.23 - GlobeNewswire
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-​clinical stage ...
01.11.23 - GlobeNewswire
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-​clinical stage ...
09.07.19 - GlobeNewswire
Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology
01.07.19 - GlobeNewswire
Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval
04.06.19 - GlobeNewswire
NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL
28.05.19 - GlobeNewswire
Nanobiotix announces the launch of curadigm : a new nanotechnology platform for healthcare
04.04.19 - GlobeNewswire
Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval
02.04.19 - GlobeNewswire
Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer
Data presented at AACR Annual Meeting 2019 In vivo study conducted alone or in collaboration with The University of Texas MD Anderson Cancer Center demonstrated: NBTXR3 in ...
26.03.19 - GlobeNewswire
Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback
Moving forward with Overall Survival (OS)-based, randomized, event-​driven clinical trial for the United States Pre-IND feedback from US Food and Drug Administration (FDA) provides ...
15.03.19 - GlobeNewswire
Nanobiotix 2018 Annual Results
Paris, France and Cambridge, Massachusetts, USA, March 15, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the “ Company ”), a clinical-​stage nanomedicine company ...
04.03.19 - GlobeNewswire
Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank
16.01.19 - GlobeNewswire
Nanobiotix Plans to Conduct Registered Public Offering in the United States
Nanobiotix Plans to Conduct Registered Public Offering in the United States Paris, France and Cambridge, Massachusetts (USA), January 16, 2019 – NANOBIOTIX SA (Euronext ...
07.01.19 - GlobeNewswire
Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3
Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-​in-class agent NBTXR3 for use in treating six cancer types - head and neck, pancreatic, ...
15.11.18 - GlobeNewswire
Nanobiotix revenues for the 3rd quarter of 2018
Paris, France and Cambridge, Massachusetts, USA, November 15, 2018 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-​stage nanomedicine company ...
19.10.18 - GlobeNewswire
NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO
16.10.18 - GlobeNewswire
Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank
26.09.18 - GlobeNewswire
Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with Soft Tissue Sarcoma (STS) and other ongoing phase I/II trials at upcoming ESMO and ASTRO annual conferences

Newssuche

Videos

newspaper
06.05.24 +6,89%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »